Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second complete remission~* ≥ 55 years of age~* Not candidates for allogeneic stem cell transplantation as decided by the panel of hematologists at the transplant center~* Patients with a HLA-haploidentical donor who should be able to provide informed consent for peripheral blood apheresis~* No severe concurrent illness that limits life expectancy to less than 2 years~Exclusion Criteria:~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Karnofsky index \<70%~* Acute promyelocytic leukemia~* Other tumor requiring treatment at the time of enrollment~* Active or prior documented autoimmune disease requiring systemic treatment~* Somatic or psychiatric disorder making the patient unable to sign informed consent

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ara-C+HaploLymphocyte+Nivo (Type: EXPERIMENTAL): Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:~\[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0~+ Nivolumab 40 mg D+5\] х 2-3 cycles
- Ara-C+ Nivo (Type: EXPERIMENTAL): Patients treated with nivolumab and intermediate dose cytarabine:~\[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1\] х 2-3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).